3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
HER2-positive Breast Cancer
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Recurrence
1
Rare Tumour
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
Temozolomide
16
Magnetic Resonance Spectroscopy
10
Etoposide
9
Cyclophosphamide
8
Radiotherapy
7
Carboplatin
7
Bevacizumab
7
Filgrastim
6
Thiotepa
5
Radiation
4
Biopsy
4
Azacitidine
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
sargramostim
3
etoposide phosphate
3
Surveys and Questionnaires
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Methotrexate
3
Irinotecan
3
Gadolinium DTPA
3
Cisplatin
3
Automobiles
3
lutetium Lu 177 dotatate
2
fluorodopa F 18
2
alovudine
2
aldesleukin
2
Yoga
2
Topotecan
2
Thalidomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Ependymoma
×
neratinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled